Mineralys Therapeutics, Inc. (Nasdaq: MLYS) provided a corporate update highlighting recent and upcoming clinical and regulatory milestones.
The company's management team will participate in the 15th LifeSci Partners Corporate Access event on January 12-14, 2026, in San Francisco, California.
The CEO, Jon Congleton, expressed confidence in the drug candidate, lorundrostat, based on its clinical data and safety profile.
Explore-OSA Phase 2 Trial
Topline results expected in Q1 2026 evaluating benefits on OSA symptoms and blood pressure.
Lorundrostat NDA
Submitted to FDA in late 2025, supported by positive clinical trial data.
Transform-HTN Open-Label Extension Trial
Continues to gather long-term safety and efficacy data for lorundrostat.
Explore-CKD Phase 2 Trial
Positive results in participants with hypertension, reduced kidney function, and albuminuria.
Pivotal Launch-HTN Phase 3 Trial
Met primary endpoint for uncontrolled or resistant hypertension treatment.
- The company's drug candidate, lorundrostat, demonstrates best-in-class profile with clinically meaningful blood pressure reduction, 24-hour control, and safety.
- Positive data from trials support lorundrostat's efficacy in treating hypertension and related conditions.
- Successful trials reinforce lorundrostat's benefit-risk profile in high-risk populations.
Mineralys Therapeutics continues to make significant progress in developing lorundrostat for the treatment of hypertension and related comorbidities. The company's recent achievements underscore the potential of lorundrostat in addressing unmet medical needs in patients with challenging conditions.